Peptide Comparison
CagriSema vs Eloralintide
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
CagriSema has stronger documented evidence (Phase 3) than Eloralintide (Phase 1/2) while both occupy the amylin class. When clinical-evidence tier is the deciding factor, CagriSema is the safer pick. Eloralintide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| CagriSema | Eloralintide | |
|---|---|---|
| Class | Amylin + GLP-1 combination | Amylin receptor agonist (investigational) |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | Dual amylin + GLP-1 receptor agonism | Long-acting amylin receptor agonist |
| Route | SC injection | SC injection |
| Half-life | ~7 days | Long-acting (weekly target) |
| Dosage (research) | 2.4 mg / 2.4 mg SC weekly | Trial doses undisclosed |
| Evidence tier | Phase 3 | Phase 1/2 |
| Research depth | 113 indexed | 34 indexed |
| Availability | Investigational | Investigational |
| Reported risks | GI effects; Phase 3 REDEFINE mixed results | Early-stage trials |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick CagriSema or Eloralintide?
CagriSema has stronger documented evidence (Phase 3) than Eloralintide (Phase 1/2) while both occupy the amylin class. When clinical-evidence tier is the deciding factor, CagriSema is the safer pick. Eloralintide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between CagriSema and Eloralintide?
CagriSema is classed as Amylin + GLP-1 combination; Eloralintide is classed as Amylin receptor agonist (investigational). Reported mechanism: CagriSema, Dual amylin + GLP-1 receptor agonism; Eloralintide, Long-acting amylin receptor agonist. Reported half-life: CagriSema, ~7 days; Eloralintide, Long-acting (weekly target). Routes in published studies: CagriSema, SC injection; Eloralintide, SC injection.
Which has stronger evidence, CagriSema or Eloralintide?
CagriSema has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CagriSema is graded Phase 3, with 25 cited sources on its reference page and 113 indexed studies. Eloralintide is graded Phase 1/2, with 24 cited sources on its reference page and 34 indexed studies.
Which is more accessible, CagriSema or Eloralintide?
Neither CagriSema nor Eloralintide is an FDA-approved drug. Catalog status: CagriSema, Investigational; Eloralintide, Investigational.
Are CagriSema and Eloralintide ever combined?
CagriSema and Eloralintide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…